

Financial news for BOTA dated on 2016-04-12: Biota Pharma Announces Will Change Name to Aviragen Therapeutics, with Nasdaq Ticker 'AVIR'

Financial news for BOTA dated on 2016-04-11: Biota Pharma Reports Initiation of Phase 2a Efficacy Trial of BTA585 for Treatment of RSV Infections

Financial news for BOTA dated on 2016-03-17: Biota Pharma to Sell Antibiotic Assets to Spero Therapeutics, No Terms Disclosed

Financial news for BOTA dated on 2016-02-26: Biota Announces Positive Results From Phase 1 Program for RSV Antiviral

Financial news for BOTA dated on 2016-02-26: Biota Reports Positive Results From Phase 1 Program for Direct Acting RSV Antiviral BTA585

Financial news for BOTA dated on 2016-02-16: Biota Receives FDA Fast Track Designation For BTA585, Phase 2 RSV Challenge Trial Expected By Q2 2016

Financial news for BOTA dated on 2016-02-08: Biota Begins Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma

Financial news for BOTA dated on 2016-01-27: HSBC Initiates Coverage on Biota Pharmaceuticals at Buy

Financial news for BOTA dated on 2016-01-20: Stocks Hitting 52-Week Lows

Financial news for BOTA dated on 2015-12-22: FBR Capital Initiates Coverage on Biota Pharmaceuticals at Outperform, Announces \$6.00 PT

Financial news for BOTA dated on 2015-12-18: Biota Announces Positive Phase 1 Data for Direct-Acting RSV Antiviral BTA585, Drug Well Tolerated At All Dose Levels And No Serious Adverse Events

Financial news for BOTA dated on 2015-11-06: Biota Pharma Reports Q1 (\$0.17) Vs Prior (\$0.20), Sales \$1.7M Vs Est \$700K

Financial news for BOTA dated on 2015-11-02: Biota Pharma Names Mark Colonnese CFO

Financial news for BOTA dated on 2015-09-22: Biota Pharmaceuticals Appoints Armando Anido and Michael Dunne, M.D. to Its Board of Directors

Financial news for BOTA dated on 2015-09-11: Biota Pharma Q4 EPS -\$0.55, Revenue \$4.1M, No Estimates

Financial news for BOTA dated on 2015-09-11: Earnings Scheduled For September 11, 2015

Financial news for BOTA dated on 2015-08-20: UPDATE: Biota Sees Commencement of Dosing in Phase 1 Multiple Ascending Dose Study in Q4'15

Financial news for BOTA dated on 2015-08-20: Biota Reports Advancement of RSV Program with Beginning of Phase 1 Trial Dosing for Direct-Acting Antiviral BTA585

Financial news for BOTA dated on 2015-06-03: Biota Pharmaceuticals Completes Acquisition of Anaconda Pharma

Financial news for BOTA dated on 2015-05-07: Biota Pharma Reports Q3 EPS \$0.03, Sales \$5.9M

Financial news for BOTA dated on 2015-03-03: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial

Financial news for BOTA dated on 2015-02-26: Biota Pharmaceuticals to Acquire Anaconda Pharma for 3.5M Shares Of Biota Stock, \$8M in Cash

Financial news for BOTA dated on 2014-11-07: Biota Pharmaceuticals Reports Q1 EPS of \$(0.20) Which May Not Compare \$(0.12) Est; Revenue of \$700.0K

Financial news for BOTA dated on 2014-09-26: Biota Pharmaceuticals Reports Q4 EPS of \$(0.29) vs \$(0.18) Est; Revenue of \$8.50M vs \$12.96M Est

Financial news for BOTA dated on 2014-09-26: Earnings Scheduled For September 26, 2014

Financial news for BOTA dated on 2014-08-04: Benzinga's Top Downgrades

Financial news for BOTA dated on 2014-08-04: Guggenheim Securities Downgrades Biota Pharmaceuticals To Neutral

Financial news for BOTA dated on 2014-08-04: Guggenheim Securities Downgrades Biota Pharmaceuticals to Neutral, Lowers PT to \$3.00

Financial news for BOTA dated on 2014-08-01: Morning Market Losers

Financial news for BOTA dated on 2014-08-01: Biota Pharma to Resume Trade at 7:30 a.m. EDT

Financial news for BOTA dated on 2014-08-01: UPDATE: Biota Issues Results of Top-Line Data from Phase 2 IGLOO Trial of Laninamivir Octanoate, Says Neither Cohort Achieved Statistical Significance in Reduction in Time

Financial news for BOTA dated on 2014-06-02: Biota to Cut Workforce by Two-Thirds

Financial news for BOTA dated on 2014-05-08: Morning Market Losers

Financial news for BOTA dated on 2014-04-29: Morning Market Losers

Financial news for BOTA dated on 2014-04-29: Biota Pharmaceuticals Shares Fall 30% Following Stop-Work Order from Department of Health and Human Services